Cheryl Scott Sells 7,439 Shares of Progyny (NASDAQ:PGNY) Stock

Progyny, Inc. (NASDAQ:PGNY) Director Cheryl Scott sold 7,439 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $26.39, for a total transaction of $196,315.21. Following the transaction, the director owned 19,772 shares of the company’s stock, valued at approximately $521,783.08. This represents a 27.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Progyny Stock Up 2.0%

Shares of PGNY opened at $25.48 on Friday. The stock has a market cap of $2.00 billion, a price-to-earnings ratio of 33.09, a P/E/G ratio of 1.33 and a beta of 1.03. Progyny, Inc. has a 12 month low of $16.10 and a 12 month high of $28.75. The company has a 50-day moving average price of $20.42 and a two-hundred day moving average price of $22.27.

Progyny (NASDAQ:PGNY) last announced its quarterly earnings results on Thursday, May 7th. The company reported $0.50 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.24. Progyny had a net margin of 5.23% and a return on equity of 13.34%. The firm had revenue of $328.50 million during the quarter, compared to analysts’ expectations of $326.47 million. During the same quarter last year, the company earned $0.17 earnings per share. The company’s revenue for the quarter was down 26.4% compared to the same quarter last year. Progyny has set its FY 2026 guidance at 1.980-2.09 EPS and its Q2 2026 guidance at 0.500-0.53 EPS. Equities research analysts expect that Progyny, Inc. will post 1.12 EPS for the current fiscal year.

Progyny declared that its board has initiated a share repurchase plan on Tuesday, May 26th that permits the company to repurchase $200.00 million in shares. This repurchase authorization permits the company to reacquire up to 10.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s management believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PGNY. BTIG Research cut their target price on shares of Progyny from $35.00 to $30.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. Truist Financial lifted their target price on shares of Progyny from $28.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Jefferies Financial Group reiterated a “buy” rating and issued a $30.00 target price on shares of Progyny in a research note on Friday, March 6th. Barclays lifted their target price on shares of Progyny from $23.00 to $27.00 and gave the company an “overweight” rating in a research note on Friday, May 15th. Finally, Zacks Research upgraded shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Thursday, May 7th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $29.67.

Institutional Trading of Progyny

Hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System raised its holdings in shares of Progyny by 0.7% in the 2nd quarter. California State Teachers Retirement System now owns 70,421 shares of the company’s stock valued at $1,549,000 after purchasing an additional 457 shares during the period. Teza Capital Management LLC raised its holdings in shares of Progyny by 5.4% in the 2nd quarter. Teza Capital Management LLC now owns 10,068 shares of the company’s stock valued at $221,000 after purchasing an additional 516 shares during the period. Aristides Capital LLC raised its holdings in shares of Progyny by 4.6% in the 3rd quarter. Aristides Capital LLC now owns 11,938 shares of the company’s stock valued at $257,000 after purchasing an additional 528 shares during the period. Leibman Financial Services Inc. raised its holdings in shares of Progyny by 1.2% in the 4th quarter. Leibman Financial Services Inc. now owns 46,435 shares of the company’s stock valued at $1,192,000 after purchasing an additional 528 shares during the period. Finally, Oxford Asset Management LLP raised its holdings in shares of Progyny by 4.3% in the 2nd quarter. Oxford Asset Management LLP now owns 12,918 shares of the company’s stock valued at $284,000 after purchasing an additional 531 shares during the period. Institutional investors and hedge funds own 94.93% of the company’s stock.

Progyny Company Profile

Progyny, Inc is a New York-based fertility benefits management company that partners with employers and health plans to design and administer comprehensive family-building programs. The company’s digital health platform integrates clinical expertise, patient support tools and data analytics to help members navigate fertility treatments, from in vitro fertilization (IVF) and egg freezing to surrogacy and adoption. By focusing on outcomes-based care, Progyny aims to improve success rates while controlling costs for its clients.

The core of Progyny’s offering is its proprietary Smart Cycle® benefit, which bundles clinical, emotional and logistical support into a single package.